Table 5.
Odds ratios (OR) and 95% confidence intervals (CI) for prevalence of hyperthyroidism: the estimated effects of I-131 thyroid dose (≥ 0.5 Gy vs. < 0.5 Gy) according to levels of other potential effect modifiers.
| Characteristic | Combined | Female | ||
|---|---|---|---|---|
|
| ||||
| ORa | 95%CI | ORa | 95%CI | |
| ATPO level, U/mL | ||||
|
| ||||
| < 60 | 1.48 | 0.76,2.76 | 1.98 | 0.92,4.04 |
| ≥ 60 | 1.26 | 0.43,3.28 | 1.70 | 0.52,4.68 |
|
| ||||
| test for heterogeneityb/interactionc | P=0.47 / P=0.78 | P=0.16 / P=0.80 | ||
|
| ||||
| Place of residency | ||||
|
| ||||
| Zhytomyr | 0.75 | 0.28,1.86 | 1.66 | 0.61,4.30 |
| Kyiv | 1.97 | 0.67,5.28 | 1.86 | 0.51,5.49 |
| Chernihiv | 1.97 | 0.82,4.24 | 2.22 | 0.73,5.61 |
|
| ||||
| test for heterogeneityb/interactionc | P=0.22 / P=0.23 | P=0.29 / P=0.91 | ||
|
| ||||
| Period of examination | ||||
|
| ||||
| Dec-Feb | 3.02 | 0.91,11.76 | 4.31 | 1.28,15.52 |
| Mar-May | 0.88 | 0.20,2.80 | 1.74 | 0.39,5.76 |
| Jun-Aug | 2.79 | 1.02,6.97 | 2.46 | 0.68,7.14 |
| Sep-Nov | 0.62 | 0.17,1.71 | 0.81 | 0.18,2.50 |
|
| ||||
| test for heterogeneityb/interactionc | P=0.09 / P=0.08 | P=0.09 / P=0.22 | ||
|
| ||||
| Ultrasound-detected nodules | ||||
|
| ||||
| No | 1.53 | 0.84,2.70 | 2.05 | 1.03,3.93 |
| Yes | 0.53 | 0.03,3.47 | 0.82 | 0.04,5.45 |
| test for heterogeneityb/interactionc | P=0.30 / P=0.31 | P=0.12 / P=0.57 | ||
|
| ||||
| Diffuse goiter | ||||
|
| ||||
| No | 1.45 | 0.77,2.63 | 2.04 | 1.00,3.96 |
| Yes | 1.31 | 0.43,3.20 | 1.42 | 0.33,4.19 |
| test for heterogeneityb/interactionc | P=0.49 / P=0.85 | P=0.14 / P=0.39 | ||
|
| ||||
| Current smoking status | ||||
|
| ||||
| No | 1.56 | 0.83,2.82 | 1.84 | 0.91,3.54 |
| Yes | 1.02 | 0.30,2.66 | 2.30 | 0.36,8.04 |
| test for heterogeneityb/interactionc | P=0.37 / P=0.45 | P=0.16 / P=0.78 | ||
|
| ||||
| Urinary iodine, μg/L | ||||
|
| ||||
| < 20 | 1.16 | 0.27,3.35 | 2.17 | 0.50,6.46 |
| ≥ 20 | 1.48 | 0.79,2.67 | 2.03 | 0.98,3.99 |
| Missing/Unknown | 1.30 | 0.21,4.36 | 0.86 | 0.05,4.12 |
|
| ||||
| test for heterogeneityb/interactionc | P=0.66 / P=0.92 | P=0.22 / P=0.63 | ||
|
| ||||
| Age at exposure, years | ||||
|
| ||||
| 0–4 | 0.54 | 0.15,1.57 | 0.47 | 0.07,1.91 |
| 5–9 | 1.43 | 0.56,3.17 | 1.88 | 0.68,4.50 |
| 10–14 | 1.82 | 0.71,4.09 | 3.03 | 1.15,7.11 |
| 15–18 | 5.08 | 1.40,14.65 | 4.88 | 0.73,19.42 |
|
| ||||
| test for heterogeneityb/interactionc | P=0.07 / P=0.06 | P=0.05 / P=0.12 | ||
a
All analyses performed with adjustment for gender, age at exposure by gender, place of residency, periodof examination, ATPO level, thyroid volume and ultrasound-detected nodules.
b
Based on the LRT for the no dose effect vs dichotomous effect with interaction.
c
Based on the LRT for the interaction with the dichotomous dose effect.